EMA and FDA Release Principles for AI in Drug Development

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have jointly published a set of ten principles aimed at guiding the use of artificial intelligence (AI) in drug development. This initiative comes as biopharma companies increasingly adopt AI technologies, transforming traditional processes throughout the entire product life cycle, from drug discovery to clinical testing and commercial rollout.

The list of principles is intended to inform future regulatory guidance on AI in both the US and EU, as well as contribute to international standard-setting. According to the two regulatory bodies, these principles offer “broad guidance on AI use in evidence generation and monitoring across all phases of a medicine,” encompassing early research, clinical trials, manufacturing, and safety monitoring.

Core Principles for AI Development

At the forefront of these principles is the emphasis on human-centric design. The regulators stress that AI systems must align with ethical values and be developed using a risk-based approach tailored to their specific context of use. Additionally, the development of AI technologies should adhere to existing legal, ethical, technical, scientific, cybersecurity, and regulatory standards.

The principles mandate that AI systems be developed with multidisciplinary expertise and under stringent data governance. This includes comprehensive documentation controls focused on privacy and the protection of sensitive data, alongside the implementation of best practices in model and system design as well as software engineering.

Before deployment, AI technologies must undergo risk-based performance assessments, which should include testing of human-AI interactions. Continuous monitoring and periodic re-evaluation are also required to ensure that these systems remain effective and relevant.

Another crucial aspect of these guidelines is the necessity for AI technologies to deliver information in clear and accessible language. This ensures that both users and patients can engage with the information meaningfully and contextually.

Regulatory Support and Industry Trends

The regulators highlight that effectively managing AI technology, including risk mitigation, is essential to harness its benefits in drug development. According to Olivér Várhelyi, the European Commissioner for Health and Animal Welfare, “The guiding principles of good AI practice in drug development are a first step of a renewed EU-US cooperation in the field of novel medical technologies.” He emphasized that these principles showcase how collaborative efforts can maintain leadership in the global innovation landscape while safeguarding patient safety.

The swift integration of AI into the biopharma sector is evidenced by a surge in partnerships between biopharma firms and AI specialists. Recent announcements include collaborations between Iktos and both Servier and Pierre Fabre, Insilico Medicines with Servier, and GSK with Noetik and Helix. Additionally, AstraZeneca has acquired Boston-based Modella AI to enhance its research and development capabilities through advanced AI models and agents.

The release of these ten principles marks a significant step towards establishing a framework for the responsible use of AI in pharmaceuticals, ensuring that innovations are not only effective but also ethically sound and beneficial to patients worldwide.